diagnostic tests. Overall, Thyrocar increased 10% price for its sick care business in B2B segment while price of few tests in preventive care marginally reduced in Q1FY20. Management guided that the benefits of price rationalization in Aarogyam 1.1, 1.2 and 1.3 will be visible in FY20E. Hence, we expect better traction in volumes and growth in the remaining three quarters of FY20E. Management guided for increased focus on B-2-B business with higher incentives and revenues per franchisee as it focusses...